134 related articles for article (PubMed ID: 17229076)
1. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome.
Levi Z; Hazazi R; Kedar-Barnes I; Hodak E; Gal E; Mor E; Niv Y; Winkler J
Am J Transplant; 2007 Feb; 7(2):476-9. PubMed ID: 17229076
[TBL] [Abstract][Full Text] [Related]
2. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
3. Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report.
Tomonari M; Shimada M; Nakada Y; Yamamoto I; Itoh M; Koike Y; Kobayashi A; Miki J; Yamada H; Kimura T; Saito S; Sugano K; Sekine S; Yamamoto H; Asahina A; Yokoo T
BMC Nephrol; 2019 Oct; 20(1):394. PubMed ID: 31664942
[TBL] [Abstract][Full Text] [Related]
4. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
Landis MN; Davis CL; Bellus GA; Wolverton SE
J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
[TBL] [Abstract][Full Text] [Related]
6. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study.
Rütten A; Burgdorf W; Hügel H; Kutzner H; Hosseiny-Malayeri HR; Friedl W; Propping P; Kruse R
Am J Dermatopathol; 1999 Oct; 21(5):405-13. PubMed ID: 10535567
[TBL] [Abstract][Full Text] [Related]
7. Resolution of Benign and Malignant Sebaceous Neoplasms, in a Renal Transplant Patient Treated With Everolimus.
Donati M; Paolino G; Muscardin L; Panetta C; Donati P
Exp Clin Transplant; 2017 Feb; 15(1):100-102. PubMed ID: 25924010
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
9. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients.
Harwood CA; Swale VJ; Bataille VA; Quinn AG; Ghali L; Patel SV; Dove-Edwin I; Cerio R; McGregor JM
J Invest Dermatol; 2001 Feb; 116(2):246-53. PubMed ID: 11180000
[TBL] [Abstract][Full Text] [Related]
10. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
[TBL] [Abstract][Full Text] [Related]
11. The Muir-Torre syndrome: a disease of sebaceous and colonic neoplasms.
Schwartz RA; Goldberg DJ; Mahmood F; DeJager RL; Lambert WC; Najem AZ; Cohen PJ
Dermatologica; 1989; 178(1):23-8. PubMed ID: 2917677
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Sebaceous Lesions in a Patient With MUTYH-Associated Polyposis Mimicking Muir-Torre Syndrome.
Kacerovska D; Drlik L; Slezakova L; Michal M; Stehlik J; Sedivcova M; Hadravsky L; Kazakov DV
Am J Dermatopathol; 2016 Dec; 38(12):915-923. PubMed ID: 27870730
[TBL] [Abstract][Full Text] [Related]
13. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
14. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
15. Muir-Torre Syndrome in a Middle-Aged Chinese Patient with Sebaceous Carcinoma of the Eyelid.
Wong CY; Tang RK; Lam RF; Io IY; Yuen CY; Ho JW; Tse RK
Semin Ophthalmol; 2015; 30(5-6):420-2. PubMed ID: 24117411
[TBL] [Abstract][Full Text] [Related]
16. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
17. All patients with sebaceous gland neoplasms should be screened for Muir-Torre syndrome.
Ingram JR; Griffiths AP; Roberts DL
Clin Exp Dermatol; 2009 Mar; 34(2):264-6. PubMed ID: 19187311
[No Abstract] [Full Text] [Related]
18. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC.
Ollila S; Fitzpatrick R; Sarantaus L; Kariola R; Ambus I; Velsher L; Hsieh E; Andersen MK; Raevaara TE; Gerdes AM; Mangold E; Peltomäki P; Lynch HT; Nyström M
Int J Oncol; 2006 Jan; 28(1):149-53. PubMed ID: 16327991
[TBL] [Abstract][Full Text] [Related]
19. A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome.
Mangold E; Pagenstecher C; Leister M; Mathiak M; Rütten A; Friedl W; Propping P; Ruzicka T; Kruse R
J Med Genet; 2004 Jul; 41(7):567-72. PubMed ID: 15235030
[No Abstract] [Full Text] [Related]
20. Borderline sebaceous neoplasm in a renal transplant patient without Muir-Torre syndrome.
Kaminska EC; Iyengar V; Tsoukas M; Shea CR
J Cutan Pathol; 2013 Mar; 40(3):336-40. PubMed ID: 23174034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]